CHARLES RIVER LABORATORIES (CRL)
US1598641074 - Common Stock
CRL gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 57 industry peers in the Life Sciences Tools & Services industry. CRL has an excellent profitability rating, but there are concerns on its financial health. CRL has a valuation in line with the averages, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
CRL had positive earnings in the past year.
CRL had a positive operating cash flow in the past year.
Each year in the past 5 years CRL has been profitable.
Each year in the past 5 years CRL had a positive operating cash flow.
1.2 Ratios
CRL's Return On Assets of 5.16% is amongst the best of the industry. CRL outperforms 84.21% of its industry peers.
CRL has a Return On Equity of 10.92%. This is amongst the best in the industry. CRL outperforms 84.21% of its industry peers.
With an excellent Return On Invested Capital value of 7.07%, CRL belongs to the best of the industry, outperforming 82.46% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for CRL is in line with the industry average of 9.66%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.16% | ||
| ROE | 10.92% | ||
| ROIC | 7.07% |
ROA(3y)5.92%
ROA(5y)5.95%
ROE(3y)14.99%
ROE(5y)15.52%
ROIC(3y)8.07%
ROIC(5y)7.97%
1.3 Margins
CRL has a Profit Margin of 10.17%. This is amongst the best in the industry. CRL outperforms 84.21% of its industry peers.
In the last couple of years the Profit Margin of CRL has grown nicely.
CRL has a Operating Margin of 15.04%. This is amongst the best in the industry. CRL outperforms 80.70% of its industry peers.
CRL's Operating Margin has been stable in the last couple of years.
CRL's Gross Margin of 35.93% is in line compared to the rest of the industry. CRL outperforms 40.35% of its industry peers.
In the last couple of years the Gross Margin of CRL has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 15.04% | ||
| PM (TTM) | 10.17% | ||
| GM | 35.93% |
OM growth 3Y0.93%
OM growth 5Y0.35%
PM growth 3Y-2.65%
PM growth 5Y2.84%
GM growth 3Y0.29%
GM growth 5Y-0.02%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so CRL is destroying value.
The number of shares outstanding for CRL has been increased compared to 1 year ago.
Compared to 5 years ago, CRL has more shares outstanding
Compared to 1 year ago, CRL has an improved debt to assets ratio.
2.2 Solvency
CRL has an Altman-Z score of 2.56. This is not the best score and indicates that CRL is in the grey zone with still only limited risk for bankruptcy at the moment.
CRL's Altman-Z score of 2.56 is in line compared to the rest of the industry. CRL outperforms 52.63% of its industry peers.
CRL has a debt to FCF ratio of 4.16. This is a neutral value as CRL would need 4.16 years to pay back of all of its debts.
With a decent Debt to FCF ratio value of 4.16, CRL is doing good in the industry, outperforming 75.44% of the companies in the same industry.
CRL has a Debt/Equity ratio of 0.62. This is a neutral value indicating CRL is somewhat dependend on debt financing.
CRL has a Debt to Equity ratio of 0.62. This is in the lower half of the industry: CRL underperforms 68.42% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.62 | ||
| Debt/FCF | 4.16 | ||
| Altman-Z | 2.56 |
ROIC/WACC0.65
WACC10.93%
2.3 Liquidity
CRL has a Current Ratio of 1.48. This is a normal value and indicates that CRL is financially healthy and should not expect problems in meeting its short term obligations.
CRL's Current ratio of 1.48 is on the low side compared to the rest of the industry. CRL is outperformed by 75.44% of its industry peers.
CRL has a Quick Ratio of 1.14. This is a normal value and indicates that CRL is financially healthy and should not expect problems in meeting its short term obligations.
CRL's Quick ratio of 1.14 is on the low side compared to the rest of the industry. CRL is outperformed by 73.68% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.48 | ||
| Quick Ratio | 1.14 |
3. Growth
3.1 Past
CRL shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -9.40%.
Measured over the past years, CRL shows a quite strong growth in Earnings Per Share. The EPS has been growing by 12.09% on average per year.
Looking at the last year, CRL shows a decrease in Revenue. The Revenue has decreased by -3.67% in the last year.
Measured over the past years, CRL shows a quite strong growth in Revenue. The Revenue has been growing by 12.75% on average per year.
EPS 1Y (TTM)-9.4%
EPS 3Y9.37%
EPS 5Y12.09%
EPS Q2Q%-4.78%
Revenue 1Y (TTM)-3.67%
Revenue growth 3Y12.2%
Revenue growth 5Y12.75%
Sales Q2Q%-1.64%
3.2 Future
The Earnings Per Share is expected to grow by 6.53% on average over the next years.
The Revenue is expected to grow by 4.62% on average over the next years.
EPS Next Y-3.27%
EPS Next 2Y-1.41%
EPS Next 3Y2.84%
EPS Next 5Y6.53%
Revenue Next Year-1.74%
Revenue Next 2Y-0.29%
Revenue Next 3Y1.82%
Revenue Next 5Y4.62%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
CRL is valuated rather expensively with a Price/Earnings ratio of 18.40.
Compared to the rest of the industry, the Price/Earnings ratio of CRL indicates a rather cheap valuation: CRL is cheaper than 94.74% of the companies listed in the same industry.
CRL is valuated rather cheaply when we compare the Price/Earnings ratio to 27.30, which is the current average of the S&P500 Index.
CRL is valuated rather expensively with a Price/Forward Earnings ratio of 17.98.
Based on the Price/Forward Earnings ratio, CRL is valued cheaply inside the industry as 89.47% of the companies are valued more expensively.
CRL is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 23.80, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.4 | ||
| Fwd PE | 17.98 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of CRL indicates a rather cheap valuation: CRL is cheaper than 96.49% of the companies listed in the same industry.
96.49% of the companies in the same industry are more expensive than CRL, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 16.99 | ||
| EV/EBITDA | 12.24 |
4.3 Compensation for Growth
CRL has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)1.52
EPS Next 2Y-1.41%
EPS Next 3Y2.84%
5. Dividend
5.1 Amount
No dividends for CRL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CHARLES RIVER LABORATORIES
NYSE:CRL (12/27/2024, 8:12:45 PM)
After market: 186.16 0 (0%)186.16
-0.49 (-0.26%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners102.9%
Inst Owner Change1.18%
Ins Owners0.81%
Ins Owner Change-4.71%
Market Cap9.52B
Analysts66.4
Price Target220.21 (18.29%)
Short Float %4.3%
Short Ratio3.14
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.75%
Min EPS beat(2)5.7%
Max EPS beat(2)15.8%
EPS beat(4)4
Avg EPS beat(4)7.88%
Min EPS beat(4)1.38%
Max EPS beat(4)15.8%
EPS beat(8)8
Avg EPS beat(8)7.5%
EPS beat(12)12
Avg EPS beat(12)5.52%
EPS beat(16)16
Avg EPS beat(16)6.57%
Revenue beat(2)1
Avg Revenue beat(2)0.79%
Min Revenue beat(2)-0.86%
Max Revenue beat(2)2.43%
Revenue beat(4)3
Avg Revenue beat(4)0.94%
Min Revenue beat(4)-0.86%
Max Revenue beat(4)2.43%
Revenue beat(8)6
Avg Revenue beat(8)1.69%
Revenue beat(12)8
Avg Revenue beat(12)0.96%
Revenue beat(16)11
Avg Revenue beat(16)1.15%
PT rev (1m)-0.92%
PT rev (3m)-3.84%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-22.95%
EPS NY rev (1m)0.07%
EPS NY rev (3m)1.85%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-11.49%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.89%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.4 | ||
| Fwd PE | 17.98 | ||
| P/S | 2.34 | ||
| P/FCF | 16.99 | ||
| P/OCF | 11.96 | ||
| P/B | 2.52 | ||
| P/tB | N/A | ||
| EV/EBITDA | 12.24 |
EPS(TTM)10.12
EY5.44%
EPS(NY)10.35
Fwd EY5.56%
FCF(TTM)10.96
FCFY5.89%
OCF(TTM)15.57
OCFY8.36%
SpS79.41
BVpS73.96
TBVpS-2.36
PEG (NY)N/A
PEG (5Y)1.52
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.16% | ||
| ROE | 10.92% | ||
| ROCE | 8.74% | ||
| ROIC | 7.07% | ||
| ROICexc | 7.28% | ||
| ROICexgc | 17.16% | ||
| OM | 15.04% | ||
| PM (TTM) | 10.17% | ||
| GM | 35.93% | ||
| FCFM | 13.8% |
ROA(3y)5.92%
ROA(5y)5.95%
ROE(3y)14.99%
ROE(5y)15.52%
ROIC(3y)8.07%
ROIC(5y)7.97%
ROICexc(3y)8.39%
ROICexc(5y)8.35%
ROICexgc(3y)21.95%
ROICexgc(5y)21.28%
ROCE(3y)9.98%
ROCE(5y)9.86%
ROICexcg growth 3Y-3%
ROICexcg growth 5Y-4.51%
ROICexc growth 3Y-2.19%
ROICexc growth 5Y-3.47%
OM growth 3Y0.93%
OM growth 5Y0.35%
PM growth 3Y-2.65%
PM growth 5Y2.84%
GM growth 3Y0.29%
GM growth 5Y-0.02%
F-Score6
Asset Turnover0.51
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.62 | ||
| Debt/FCF | 4.16 | ||
| Debt/EBITDA | 2.45 | ||
| Cap/Depr | 69.29% | ||
| Cap/Sales | 5.8% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 83.71% | ||
| Profit Quality | 135.68% | ||
| Current Ratio | 1.48 | ||
| Quick Ratio | 1.14 | ||
| Altman-Z | 2.56 |
F-Score6
WACC10.93%
ROIC/WACC0.65
Cap/Depr(3y)98.14%
Cap/Depr(5y)87.25%
Cap/Sales(3y)7.45%
Cap/Sales(5y)6.68%
Profit Quality(3y)91.24%
Profit Quality(5y)102.62%
High Growth Momentum
Growth
EPS 1Y (TTM)-9.4%
EPS 3Y9.37%
EPS 5Y12.09%
EPS Q2Q%-4.78%
EPS Next Y-3.27%
EPS Next 2Y-1.41%
EPS Next 3Y2.84%
EPS Next 5Y6.53%
Revenue 1Y (TTM)-3.67%
Revenue growth 3Y12.2%
Revenue growth 5Y12.75%
Sales Q2Q%-1.64%
Revenue Next Year-1.74%
Revenue Next 2Y-0.29%
Revenue Next 3Y1.82%
Revenue Next 5Y4.62%
EBIT growth 1Y-8.35%
EBIT growth 3Y13.24%
EBIT growth 5Y13.15%
EBIT Next Year22.61%
EBIT Next 3Y10%
EBIT Next 5Y10.2%
FCF growth 1Y100.42%
FCF growth 3Y-1.3%
FCF growth 5Y4.21%
OCF growth 1Y29.64%
OCF growth 3Y7.76%
OCF growth 5Y9.35%